The FDA approved the first gene therapy for pediatric Sanfilippo syndrome type A and launched a new Expedited IND Pilot in the same week, while CMS expanded its value-based care model to cover three in four Medicare beneficiaries and integrated Oura wearable technology into chronic care delivery. The simultaneous acceleration of regulatory innovation and federal adoption of digital health tools signals a structural shift in how novel therapies reach patients and how technology-enabled care gets reimbursed.
FDA accelerates on multiple fronts
Ultragenyx Pharmaceutical's Fayuvi received FDA approval on September 17, 2026, as the first therapy targeting the underlying cause of Sanfilippo syndrome type A. Scholar Rock's Isembyld also won first-in-class approval for spinal muscular atrophy as the first therapy directly targeting muscle tissue. The back-to-back rare disease approvals came alongside the September 15 launch of an Expedited IND Pilot, which creates a new fast lane for clinical trial initiation.
The agency also scheduled a September 23 workshop on the GLP-1 generic drug pathway and a DIA/FDA Oligonucleotide-Based Therapeutics Conference for the same date. The pilot represents a regulatory acceleration mechanism that could compress development timelines for gene therapy, oligonucleotide, and rare disease programs.
CMS puts wearables and value-based care at center stage
CMS announced it will expand its ACCESS model starting spring 2027 to cover heart failure, COPD, substance use disorders, and tobacco cessation. The outcomes-based payment model, which launched in July with 160 participating providers, will make roughly three in four Medicare beneficiaries eligible for at least one track. CMS also tapped Oura to join the ACCESS model as an early example of wearable-enabled chronic care delivery.
The Oura integration establishes a federal reimbursement pathway precedent for consumer wearables in chronic disease management. Other wearable companies now have a template for entering value-based care models through outcomes-based payment structures rather than traditional device reimbursement.
AI governance failures become publicly documented
Fierce Healthcare reported that CMS's WISeR AI prior authorization pilot experienced sweeping issues including delayed approvals, miscommunication, and provider frustration, based on documents obtained by a privacy nonprofit. These are the first publicly documented failures showing that AI-driven prior authorization at scale produces operational problems, not just theoretical risks.
The revelations arrive as the broader AI governance debate intensifies. MedCity News published commentary arguing that "shadow AI is the fastest-growing force in medicine" and that hospitals are the only ones who can control it. KFF Health News released a podcast episode on the health risks of AI. The convergence of documented failures and media scrutiny marks a turning point where AI governance shortcomings are becoming politically salient.
USPSTF overhaul introduces preventive care uncertainty
RFK Jr. named eight new members to the USPSTF panel, nearly four months after dismissing the task force's two vice chairs. The AMA issued a statement saying the composition "represents a significant departure from USPSTF's traditional membership" and called for a strong primary care voice to remain central to its work.
The restructuring introduces uncertainty into preventive care screening standards. If the new membership shifts evidence thresholds for screening recommendations, payer coverage decisions for cancer screening, cardiovascular risk assessment, and behavioral health screening tools could change. Digital health companies with products tied to USPSTF-recommended screenings should monitor the new panel's first guidance outputs closely.
Hospital margins fall as capital migrates to digital health
Hospital operating margins fell to 1.4% in July, down from 2.2% in May and June, driven by a seasonal slowdown in elective surgeries and payer mix pressures, according to Kaufman Hall data. As Medicare Advantage denial rates climb, health systems are dropping plans and steering patients back to traditional Medicare. Pearl Health CEO Michael Kopko said "the original Medicare Advantage bargain has broken down."
Meanwhile, digital health funding continued across multiple categories. Sword Health confirmed its acquisition of Headspace, targeting Q4 completion. Thatch reached unicorn status after a $108 million Series C. Ayble Health secured $16 million for a virtual digestive health clinic. Angle Health raised $600 million, reaching a $2.7 billion valuation. The contrast suggests capital and care delivery are both migrating away from traditional hospital-centric models toward distributed, technology-enabled platforms.
International regulators advance digital health frameworks
Japan's PMDA updated its Software as a Medical Device regulatory page on September 18, revising its guide, publishing seminar materials, and updating the consultation schedule. PMDA also approved a new companion diagnostic and implemented harmonized texts into the Japanese Pharmacopoeia. The UK's MHRA opened a call for evidence on AI for medicines safety on September 16, seeking input on using AI for safety assessment beyond traditional ADMET frameworks. NICE recommended Enhertu for routine NHS use in approximately 1,000 patients with HER2-low advanced breast cancer.
The concurrent updates across Japan and the UK create a multi-jurisdictional regulatory environment where companies must simultaneously satisfy evolving AI and companion diagnostic standards across three major markets. Professionals navigating these requirements may benefit from AI Regulatory Compliance Courses that address cross-market submission strategies.
Why this matters for healthcare professionals
The documented WISeR AI pilot failures will strengthen the hand of physician organizations and state legislators pushing for AI prior authorization guardrails, and may accelerate federal rulemaking on AI in coverage decisions. Vendors and payers deploying AI in clinical workflows face increasing scrutiny from regulators, media, and other stakeholders - not just theoretical warnings. The Cochrane review finding that exercise-based cardiac rehabilitation reduces hospital admissions by a third, with home-based and digitally supported programs proving as effective as center-based services, provides high-quality evidence that strengthens the reimbursement case for remote cardiac rehab platforms. For health systems facing 1.4% margins, the financial pressure creates a structural incentive to accelerate AI adoption for operational efficiency, favoring tools that can show near-term administrative cost reduction.
Your membership also unlocks:
